Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects-Reference-Cited by-同舟云学术

Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects

Published:2020-04-04 Issue:5 Volume:85 Page:899-906
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Ogasawara Ken^ORCID,Xu Christine,Kanamaluru Vanaja,Palmisano Maria,Krishna Gopal^ORCID

Funder

Bristol-Myers Squibb

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-020-04067-3.pdf

Reference19 articles.

1. Furqan M, Mukhi N, Lee B, Liu D (2013) Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res 1(1):5. https://doi.org/10.1186/2050-7771-1-5

2. Schwartz DM, Bonelli M, Gadina M, O'Shea JJ (2016) Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol 12(1):25–36. https://doi.org/10.1038/nrrheum.2015.167

3. Vainchenker W, Constantinescu SN (2013) JAK/STAT signaling in hematological malignancies. Oncogene 32(21):2601–2613. https://doi.org/10.1038/onc.2012.347

4. Romano M, Sollazzo D, Trabanelli S, Barone M, Polverelli N, Perricone M et al (2017) Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis. Oncoimmunology 6(10):e1345402. https://doi.org/10.1080/2162402X.2017.1345402

5. U.S. Food and Drug Administration. INREBIC (fedratinib) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf. Accessed 12 Nov 2019

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in physiologically based pharmacokinetic modeling for fedratinib: updating dose guidance in the presence of a dual inhibitor of CYP3A4 and CYP2C19;Cancer Chemotherapy and Pharmacology;2024-08-07

2. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis;Expert Review of Hematology;2023-03-21

3. Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults;Cancer Chemotherapy and Pharmacology;2022-08-24

4. Antifungal Drugs TDM: Trends and Update;Therapeutic Drug Monitoring;2022-02

5. Predicting the Drug–Drug Interaction Mediated by CYP3A4 Inhibition: Method Development and Performance Evaluation;The AAPS Journal;2021-12-10